Manejo multidisciplinario en retinoblastoma: experiencia en 37 ojos

Ossandón, D.; Zanolli, Mario; Pérez, Verónica; Rojas, J Tomás; Quijarro, P.; Kabalan, P.; Álvarez, Daniel Nehme; Varas, Mónica

doi:10.1016/j.oftal.2014.09.015

Cited by 9 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the seven eyes treated with IVM in our hospital, 39 the response was as expected; three eyes with vitreous seedings (43%) were successfully treated. Therefore, the results are similar to other published studies.…”

Section: Discussionsupporting

confidence: 71%

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol

Solana-Altabella¹,

Valero²,

Balaguer³

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Retinoblastoma is the most common paediatric ocular tumour, which appears in the retina. Without treatment, retinoblastoma grows and destroys the internal ocular globe architecture, even leading to metastasis. When treated, overall survival is close to 97%, the alkylating drug melphalan being the most extensively used chemotherapeutic agent in localised treatment. The aim of this study is to describe the implementation of a new intravitreal chemotherapy retinoblastoma treatment protocol for children implanting vitreous seeds through intravitreal melphalan injections and to evaluate the patients' health outcomes treated with it. Between December 2014 and July 2018, seven patients were treated with this protocol. They received a mean of 3.3 cycles of intravitreal melphalan with standard doses of 30 mcg per cycle. In the seven eyes treated in our hospital, the response was as expected; three eyes with vitreous seedings (43%) were successfully treated. The main adverse effects presented by all patients were scars at cryogenisation points. In two patients, the appearance of 'salt and pepper' retinopathy was reported. Oncology pharmacists, as part of the treatment team, can provide information about recommended doses, expected adverse effects, stability of preparations, most appropriate method of processing, packaging, and methods of drug administration, to ensure efficacy and especially safety in the administration of these drugs.

show abstract

Section: Discussionsupporting

confidence: 71%

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol

Solana-Altabella¹,

Valero²,

Balaguer³

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Tumor characteristics of RB patients in this study were mostly similar to those reported by prior studies in tertiary centers. 8 19 20 21 Survival rates for eyes treated with IAC after recurrence/incomplete response with primary systemic chemotherapy were marginally lower in this study (51.4%) relative to those in prior studies. For instance, Shields et al reported 62% globe salvage for secondary treated eyes 8 and Gobin et al reported 58.4% globe salvage for eyes that failed to respond to systemic chemotherapy prior to IAC.…”

Section: Discussioncontrasting

confidence: 61%

Five-Year Experience in Treatment of Retinoblastoma with Intra-Arterial Chemotherapy

Dehghani

Ghassemi

Mahmoudzadeh

et al. 2021

Journal of Current Ophthalmology

View full text Add to dashboard Cite

Purpose: To report our 5-year experience in treating retinoblastoma (RB) with intra-arterial chemotherapy (IAC) as a primary or secondary therapy, without adjuvant intravitreal chemotherapy. Methods: A retrospective study was conducted on 70 eyes with intraocular RB that were treated with primary or secondary IAC from December 2010-2015. Demographic characteristics, clinical features, tumor control, and treatment complications were compared and reported. Results: Thirty-seven eyes had received IAC as a secondary therapy after failed/incomplete response to systemic chemotherapy, and 33 eyes had received IAC as a primary treatment. The mean age of patients was 25 ± 8.9 months, and the patients were followed for a mean of 24.5 ± 16.26 months. Overall, enucleation rates were significantly higher in advanced tumors (Group D and E) in both groups (both P < 0.05). The main reason for enucleation in this study group was being unresponsive to treatment (27.4%), with 76% of latter patients having vitreous seeds at the time of enucleation. Enucleation rates did not differ significantly between patients receiving primary (18/33, 54%) or secondary IAC (18/37, 48%) ( P = 0.06). In addition, recurrence and complication rates did not differ significantly between eyes receiving IAC as their primary or secondary treatment ( P > 0.05). Conclusion: In primary and secondary treatment of RB with IAC, the main findings that are globe salvage, recurrence, and complication rates were comparable when no adjuvant intravitreal chemotherapy was used.

show abstract

“…4 In addition, said diagnostic influences therapeutic decisions, as some authors recommend that all germinal retinoblastoma patients should receive systemic chemotherapy to prevent the expression of new tumors and pineoblastoma. 1,3 In our country, survival is comparable to that of developed countries, 5,6 although mortality in Latin America remains close to 20%. 1,3 In our country, survival is comparable to that of developed countries, 5,6 although mortality in Latin America remains close to 20%.…”

Section: Introductionmentioning

confidence: 66%

Molecular diagnosis in patients with retinoblastoma: Report of a series of cases

Ossandón

Zanolli

López

et al. 2016

Archivos de la Sociedad Española de Oftalmología (English Editi

Self Cite

View full text Add to dashboard Cite

Manejo multidisciplinario en retinoblastoma: experiencia en 37 ojos

Cited by 9 publications

References 33 publications

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol

Five-Year Experience in Treatment of Retinoblastoma with Intra-Arterial Chemotherapy

Molecular diagnosis in patients with retinoblastoma: Report of a series of cases

Contact Info

Product

Resources

About